Journal
CEPHALALGIA
Volume 38, Issue 2, Pages 215-224Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0333102417737765
Keywords
Migraine; headache; triptan; zolmitriptan; drug delivery; intracutaneous; Adhesive Dermally Applied Microarray
Categories
Ask authors/readers for more resources
Objective To determine the efficacy, tolerability, and safety of ascending doses of Adhesive Dermally-Applied Microarray (ADAM) zolmitriptan versus placebo for acute migraine treatment. Background ADAM is a novel patient-administered system for intracutaneous drug administration. In a phase 1 pharmacokinetic study, zolmitriptan administered using ADAM had much faster absorption than oral administration with higher exposure in the first two hours. Methods This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2b/3 study evaluating ADAM zolmitriptan 1mg, 1.9mg, and 3.8mg versus placebo. Co-primary endpoints were pain freedom and freedom from most bothersome other migraine-associated symptom 2 hours post-dose. Results Of patients treated with ADAM zolmitriptan 3.8mg or placebo, 41.5% and 14.2%, respectively were pain-free 2 hours post-dose (p=0.0001) and 68.3% and 42.9% were free from their most bothersome other symptom (p=0.0009). Due to the fixed sequential testing methodology, formal statistical significance was not established for secondary endpoints. However, the proportion of patients who were photophobia-free, phonophobia-free, and nausea-free at 2 hours post-dose was higher in the ADAM zolmitriptan 3.8mg group compared with placebo, as were the percentages of patients who were pain-free, and who experienced pain relief up to 48 hours post-dose. Systemic adverse events were consistent with previous triptan trials, and included dizziness, paresthesia, muscle tightness, and nausea, all of which occurred in<5% of patients in any group. Application site reactions were generally mild and resolved within 48 hours, although erythema and bruising persisted for longer periods in some patients. Conclusion ADAM zolmitriptan 3.8mg provides effective relief of migraine headache and associated most bothersome symptoms compared with placebo, and is well-tolerated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available